Overview of Dr. Bishop
Dr. Michael Bishop is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Illinois College of Medicine at Chicago and has been in practice 32 years. He is one of 123 doctors at University of Chicago Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
5841 S. MARYLAND AVENUE
M/C 2115
Chicago, IL 60637Fax+1 773-702-0963- Is this information wrong?
Clinical Expertise
- Amyloidosis, Non-Hodgkin lymphoma, Hematologic oncology, Myelodysplasia, Myelofibrosis, Hematopoietic stem cell transplantation, Multiple myeloma, Lymphoma, Stem cell transplantation, Leukemia, Adoptive immunotherapy, Cellular Therapy, Myelodysplastic syndromes , Bone marrow transplantation, Oropharyngeal lymphoma, Angiocentric lymphoma, Acute myeloid leukemia
Education & Training
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1986 - 1988
- McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1985 - 1986
- University of Illinois College of MedicineClass of 1985
- University of Illinois - Urbana-ChampaignB.S., Biology - Ecology, Ethology, and Evolution, 1981
Certifications & Licensure
- IL State Medical License 1986 - 2026
- WI State Medical License 2011 - 2025
- NE State Medical License 1992 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Included in Castle Connolly America's Top Doctors (Medical Oncology) 2013-2021
- Included in The Best Doctors in America, National 2001-2003, 2007-2009, 2011-2020
- Fellow, American Society fo Clincial Oncology (FASCO) American Society of Clinical Oncology, 2018
- Join now to see all
Clinical Trials
- Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation Start of enrollment: 2017 Feb 08
- Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Start of enrollment: 2019 Nov 18
- TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) Start of enrollment: 2018 Dec 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, E...> ;Haematologica. 2024 Apr 11
- Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.Alexandra E Rojek, Justin P Kline, Nicholas Feinberg, Daniel E Appelbaum, Yonglin Pu, Benjamin A Derman, Andrzej Jakubowiak, Satyajit Kosuri, Hongtao Liu, Mariam T Naw...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
- 5 citationsEfficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali K Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J V...> ;Blood Advances. 2023 Aug 22
- Join now to see all
Journal Articles
- High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor ResponsesFowler DH, Mossoba ME, Halverson DC, Kurlander R, Blacklock Schuver B, Carpenter AE, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche JC, Sportes C, ..., Clin Cancer Res, 1/12/2015
- Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipientsYew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y, Bone Marrow Transplant, 1/8/2015
- Symptom distress predicts long-term health and well- being in allogeneic stem cell transplantation survivorsBevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L, Biol Blood Marrow Transplant, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...Michael R. Bishop, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Cellular Immunotherapy Including Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-cells for Hematologic MalignanciesChicago, IL - 1/30/2015
- Immunotherapy: Revolutionizing the Way We Treat Hematologic MalignanciesChampaign, IL - 1/27/2015
- Join now to see all
Other
- Alternative Donor Sources in Allogeneic Stem Cell Transplantation.Bishop MR, Medscape Oncology
1/1/1998 - Non-Hodgkin's Lymphoma and Autologous Stem Cell Transplantation: A Critical Review.Bishop MR, Bierman PJ, Vose JM, Armitage JO, Revisions en Cancer
1/1/1994 - Discovery--And Implications--Of a Single Human Bone Marrow Stem Cell.Bishop MR, Oncology Bulletin
1/1/1993 - Join now to see all
Press Mentions
- BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-cell Non-Hodgkin LymphomaDecember 20th, 2019
- Staggering Prices Slow Insurers’ Coverage of CAR-T Cancer TherapyJuly 17th, 2018
- Insurers and Government Are Slow to Cover Expensive CAR-T Cancer TherapyJuly 17th, 2018
- Join now to see all
Professional Memberships
- Fellow
- Member
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: